RxDoctor Payments Data

Kimberly Oberloh

Nurse Practitioner · Rapid City, SDNPI 1699159186

Payments from drug & device makers

$1,545in general payments, 2019–2025

Across 61 payments — averaging $25.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$348
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$234
  • AbbVie$203
  • Madrigal Pharmaceuticals$144
  • Neurocrine Biosciences, Inc.$98
  • Alkermes, Inc.$85
  • plus $433 from 14 others

What the payments were for

  • Food & beverage$1,49797%
  • Education$493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,545 in reported general payments places this provider in the 85th percentile of 504 nurse practitioner providers in South Dakota.

See all nurse practitioner providers in South Dakota

Medicare billing

Part B allowed, 2024
$199,240
Medicare patients
257
Services billed
6,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$75,162
JardianceEmpagliflozin38$58,633
OzempicSemaglutide40$45,333
MounjaroTirzepatide12$12,176
Atorvastatin Calcium436$4,990
Metoprolol Succinate185$3,248
Losartan Potassium327$3,095
SynthroidLevothyroxine Sodium31$2,382
Omeprazole256$2,331
Rosuvastatin Calcium122$2,320
Duloxetine Hcl86$2,213
Potassium Chloride98$2,187
Levothyroxine Sodium223$1,937
Lisinopril228$1,831
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$31$58,63338 claims
Novo NordiskOzempic$20$45,33340 claims
Lilly USA, LLCMounjaro$34$12,17612 claims
AbbVieSynthroid$203$2,38231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 504 nurse practitioner providers in South Dakota.

Other nurse practitioner in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →